TAO WANG

2 months ago | nature.com | Che-Hsing Li |Sandhya Sharma |Andras Heczey |Mae Woods |Sachin G. Thakkar |Mengfen Wu | +7 more

In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein–Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells—each expressing chimeric antigen receptors (CARs) targeting GD2 but without an embedded co-stimulatory sequence (first-generation CARs). These CARs incorporated barcoded sequences to track each infused population. We previously reported outcomes up to 5 years and now report long-term outcomes up to 18 years. Of 11 patients with active disease at infusion, three achieved a complete response that was sustained in two patients, one for 8 years until lost to follow-up and one for more than 18 years. Of eight patients with no evidence of disease at the time of CAR-T administration, five are disease free at their last follow-up between 10 years and 15 years after infusion. Intermittent low levels of transgene were detected during the follow-up period with significantly greater persistence in those who were long-term survivors. Despite using first-generation vectors that are no longer employed because of the lack of co-stimulatory domains, patients with relapsed/refractory neuroblastoma achieved long-term disease control after receiving GD2 CAR-T cell therapy, including one patient now in remission of relapsed disease for more than 18 years. ClinicalTrials.gov identifier: NCT00085930 . In an extended follow-up of a phase 1 trial evaluating a first-generation GD2-directed CAR-T cell therapy in patients with neuroblastoma, one patient has had a sustained clinical response for over 18 years without requiring any additional therapy, with translational data from long-term survivors providing broader insights into potential determinants of CAR-T cell response.

Jan 20, 2025 | mdpi.com | Xianliang Liu |Bo Peng |TAO WANG |Alex Molassiotis

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 14, 2025 | biorxiv.org | TAO WANG

AbstractBackground: Radiation therapy is one cornerstone of oncologic treatment. Radiation-induced skin injury (RISI) is a dose-limiting complication of radiotherapy. RISI is also common in victims of accidental exposure, which often aggravates the patient's condition and becomes a difficult medical issue. However, the damage mechanisms of RISI remain unclear, and the prevention and treatment measures are limited. An appropriate animal model holds great significance for addressing these issues.

Jan 10, 2025 | science.org | Daniel Rabe |Matthew Weller |Bhoktear Khan |TAO WANG

AbstractPerovskite oxides have a wide variety of physical properties that make them promising candidates for versatile technological applications including nonvolatile memory and logic devices. Chemical tuning of those properties has been achieved, to the greatest extent, by cation-site substitution, while anion substitution is much less explored due to the difficulty in synthesizing high-quality, mixed-anion compounds.

Jan 6, 2025 | mdpi.com | TAO WANG

Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.